Diagnostic Contract Manufacturing Market Report 2026

The diagnostic contract manufacturing market size has grown rapidly in recent years. It will grow from $35.81 billion in 2025 to $40.95 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to high capital requirements for in-house manufacturing, regulatory complexity, growing diagnostic product launches, demand for manufacturing flexibility, globalization of supply chains.

The diagnostic contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $66.08 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to growth in diagnostic innovation, demand for rapid scale-up, automation adoption, regional manufacturing expansion, focus on resilient supply chains. Major trends in the forecast period include increasing outsourcing of diagnostic manufacturing, rising demand for regulatory-compliant manufacturing services, expansion of end-to-end cdmo capabilities, growing focus on cost optimization and scalability, adoption of automated and smart manufacturing processes.

The growing emphasis on preventive healthcare is expected to drive the growth of the diagnostic contract manufacturing market in the coming years. Preventive healthcare includes measures aimed at avoiding the onset or progression of diseases, illnesses, or injuries. The increasing focus on preventive care is driven by rising healthcare costs, changing healthcare priorities, the growing burden of chronic diseases, and aging populations. Diagnostic contract manufacturing supports preventive healthcare by supplying essential diagnostic tools and tests, delivering customized solutions, ensuring quality and regulatory compliance, enabling scalable production, and offering cost-effective options for early disease detection and intervention. For instance, in October 2025, according to Eurostat, a Luxembourg-based government agency, preventive care accounted for 3.7% of total healthcare spending in the European Union in 2023. Among EU member states, the share was highest in the Netherlands at 5.2% and lowest in Malta at 0.9%. Therefore, the increasing focus on preventive healthcare is driving the growth of the diagnostic contract manufacturing market.

Major companies operating in the diagnostic contract manufacturing market are concentrating on developing advanced solutions such as one-stop chemiluminescence immunoassay (CLIA) platforms to improve assay sensitivity, optimize production workflows, and meet the rising demand for high-throughput and accurate diagnostic testing. A one-stop CLIA platform is an integrated manufacturing model in which a single contract manufacturer provides raw materials, reagent development, open-system analyzers, and large-scale production, unlike traditional fragmented manufacturing approaches. For instance, in April 2023, Fapon Biotech Inc., a China-based in vitro diagnostics solutions provider, launched its chemiluminescence one-stop solution strategy, introducing compact and high-throughput open-system CLIA analyzers such as Shine i1000 and Shine i2000, along with more than 100 CLIA reagents covering tumor, cardiac, infectious disease, thyroid, and inflammation biomarkers. This solution is designed to help diagnostic companies accelerate product launches, expand test menus, reduce per-test costs, and better align with local manufacturing requirements through high-quality raw materials and flexible reagent development support.

In August 2023, RQM Ltd., a US-based MedTech services provider, acquired Kottmann GmbH for an undisclosed amount. With this acquisition, RQM aims to improve operational efficiency, speed up client market entry, and strengthen its position as a leading MedTech contract research organization in Europe and globally. Kottmann GmbH is a Germany-based contract research organization specializing in clinical studies involving medical devices, in vitro diagnostics, and pharmaceuticals.

Major companies operating in the diagnostic contract manufacturing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Jabil Inc., Flex Ltd., Becton Dickinson and Company (BD), Sekisui Diagnostics LLC, Sanmina Corporation, Celestica Inc., Nipro Medical Corporation, Philips-Medisize Corporation, Plexus Corp, West Pharmaceutical Services Inc., Benchmark Electronics Inc., Bio-Rad Laboratories, QIAGEN N.V., Kimball Electronics Inc., Integer Holdings Corporation, Bio-Techne Corporation, Nolato AB, Nova Biomedical Corporation, Meridian Bioscience Inc., Fujirebio Inc., Biokit S.A., Invetech Pty. Ltd., KMC Systems, Savyon Diagnostics Ltd., Prestige Diagnostics U.K. Ltd., Cenogenic Corporation, Avioq Inc.

North America was the largest region in the diagnostic contract manufacturing market in 2025. The regions covered in the diagnostic contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diagnostic contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diagnostic contract manufacturing market by increasing costs of imported raw materials, components, manufacturing equipment, and packaging supplies. CDMOs in North America and Europe are most affected due to global sourcing dependencies, while Asia-Pacific faces higher equipment import costs. These tariffs increase production expenses. However, they promote localized manufacturing and regional supply chain strengthening.

The diagnostic contract manufacturing market research report is one of a series of new reports that provides diagnostic contract manufacturing market statistics, including diagnostic contract manufacturing industry global market size, regional shares, competitors with a diagnostic contract manufacturing market share, detailed diagnostic contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic contract manufacturing industry. This diagnostic contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diagnostic contract manufacturing involves the outsourcing of manufacturing processes and related services by diagnostic companies to specialized contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs). This approach allows diagnostic companies to streamline production operations, maintain quality and regulatory compliance, and improve cost efficiency by leveraging the expertise of specialized manufacturing partners.

The main service types in diagnostic contract manufacturing include device development and manufacturing services, quality management services, packaging and assembly services, and others. Device development and manufacturing services cover the design, development, and production of medical devices, including in vitro diagnostic devices and diagnostic imaging equipment. These services support applications such as in vitro diagnostic devices, diagnostic imaging devices, and others, and are utilized by end users including medical device companies, pharmaceutical and biopharmaceutical companies, and others.

The diagnostic contract manufacturing market includes revenues earned by entities through supply chain management, regulatory support, post-market surveillance, logistics, and distribution. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.